Skip to main content

Table 1 Cumulative probability (95 % CI) of achieving first LDA/remission or sustained LDA/remission

From: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)

  First time point at which 95 % CI did not overlap, day Cumulative probability (95 % CI) of achieving the specified state according to the different indices
Month 6 Month 12
Abatacept + MTX MTX alone Abatacept + MTX MTX alone
First LDA DAS28 85 57.6 (50.9, 64.3) 43.5 (36.8, 50.3) 80.6 (75.2, 86.0) 67.6 (61.1, 74.0)
CDAI 85 60.5 (53.9, 67.1) 43.5 (36.8, 50.3) 83.3 (78.3, 88.4) 69.3 (63.0, 75.6)
First remission DAS28 57 40.0 (33.4, 46.6) 27.3 (21.3, 33.3) 70.2 (63.9, 76.4) 50.4 (43.5, 57.3)
CDAI 225 22.9 (17.2, 28.5) 14.4 (9.6, 19.1) 48.4 (41.6, 55.2) 31.2 (24.8, 37.5)
First sustained LDA DAS28 57 54.8 (48.0, 61.5) 33.0 (26.6, 39.4)
CDAI 57 58.6 (51.9, 65.2) 37.3 (30.8, 43.9)
First sustained remission DAS28 113 38.6 (32.0, 45.2) 20.6 (15.1, 26.1)
CDAI 141 24.8 (18.9, 30.6) 10.5 (6.4, 14.7)
  1. Based on as-observed analyses for patients with data available at baseline, month 6 and month 12. Cumulative probability evaluated based on Kaplan–Meier estimation with corresponding 95 % CI. First remission/LDA was defined by the first visit when the patient reached remission/LDA according to DAS28 and CDAI scores. Sustained remission/LDA was defined as first remission or LDA status (according to DAS28 and CDAI scores) maintained at all subsequent visits up to month 12; patients who lost remission/LDA status were censored at the time of remission/LDA loss. CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score 28, LDA low disease activity, MTX methotrexate